Riskpilot← Back to searchSign inGet full accessStemSight Oy
OYActiveY-tunnus 3204409-1Biokatu 12Manufacture of pharmaceutical preparations · NACE 2120Est. 202110 employees
Revenue 2024
EUR 0
EBITDA margin
—
-40% vs 2023
Equity ratio
45.9%
Financial strength
Net profit 2024
EUR -710K
-63% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR -517K | -40% |
| Net profit | EUR -710K | -63% |
| Total assets | EUR 1,5M | +64% |
| Equity | EUR 680K | +256% |
| Employees | 10 | — |
Legal name
StemSight Oy
Y-tunnus number
3204409-1
Legal form
Osakeyhtiö
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
14. huhtikuuta 2021
Share capital
EUR 4 000
Employees
10 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on lääkkeiden ja muiden lääkevalmisteiden valmistus. Yhtiö voi toimintaansa varten omistaa ja hallita osakkeita, osuuksia ja kiinteistöjä sekä käydä niillä kauppaa ja vuokrata niitä.
Address
Biokatu 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 92 | 0 |
| Staff expenses | −257 | −200 | −385 |
| EBITDA | −393 | −369 | −517 |
| Depreciation & amort. | −21 | −57 | −87 |
| EBIT | −414 | −426 | −604 |
| Net financials | −0 | −10 | −106 |
| Profit before tax | −414 | −436 | −710 |
| Tax | −0 | −0 | −0 |
| Net profit | −414 | −436 | −710 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 184 | 904 | 1 482 |
| Equity | 1 | −435 | 680 |
| Long-term debt | 33 | 311 | 417 |
| Short-term debt | 150 | 1 028 | 386 |
| Total debt | 183 | 1 339 | 803 |
EBITDA margin
-51742200.0%
This company
15.8%
Market median
-327482378% vs market
20222024
Equity ratio
45.9%
This company
38.2%
Market median
+20% vs market
20222024
Return on equity
-104.4%
This company
18.4%
Market median
-667% vs market
20222024
Net profit margin
-70972400.0%
This company
8.1%
Market median
-876202569% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
1.18×
This company
0.62×
Market median
-90% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AM Person with significant control | Person with significant control | 2023 |
LF Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
| Audit | 2021 – 2023 | |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2023 – 2025 | |
| Board of Directors | 2021 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of StemSight Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Matilda Katarina Ehrnrooth | Person with significant control | 0 companies |
| Laura Fanny Johanna Koivusalo | Chief Executive Officer | 0 companies |
| Pekka Kalevi Johannes Hiltunen | Audit | 0 companies |
| Sven Johan Hyllner | Board of Directors | 0 companies |
| Ross Alexander Macdonald | Board of Directors | 0 companies |
| Maarit Hannele Merla | Board of Directors | 0 companies |
| Jyrki Lauri Liljeroos | Board of Directors | 0 companies |
| Hannu Mauno Tapio Uusitalo | Board of Directors | 0 companies |
| Anni Eveliina Mörö | Board of Directors | 0 companies |